Clinical Trial Update: Liposomal Irinotecan, Vincristine, Temozolomide, and Anlotinib for R/R Pediatric Solid Tumors [Phase 2]

View source ↗

Summary

This clinical trial update outlines a Phase 2 study evaluating a combination of liposomal irinotecan, vincristine, temozolomide, and anlotinib for relapsed or r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ewing Sarcoma
• Neuroblastoma
• Osteosarcoma
• Rhabdomyosarcoma

Drugs mentioned

• Anlotinib (anlotinib)
• Onivyde (liposomal irinotecan) (liposomal irinotecan)
• Temozolomide (Temozolomide)
• Vincristine (vincristine)

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: Relapsed or Refractory Pediatric Malignant Solid Tumors (Including Neuroblastoma, Rhabdomyosarcoma, Ewing Sarcoma, Osteosarcoma) | Phase 2 | Status: NOT_YET_RECRUITING